The development and application of small molecule modulators of SF3b as therapeutic agents for cancer

Drug Discovery Today

Volumn 18, Issue 1-2, 2013, Pages 43-49

  Webb, Thomas R ^a   Joyner, Amanda S ^a   Potter, Philip M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING NUCLEIC ACID METABOLISM; ANTINEOPLASTIC AGENT; E 7107; FR 901464; HERBOXIDIENE; INTEIN; MEAYAMYCIN; MESSENGER RNA PRECURSOR; NATURAL PRODUCT; PLADIENOLIDE B; SF3B PROTEIN; SMALL NUCLEAR RNA; SPLICEOSOME MODULATOR; SPLICEOSTATIN; SUDEMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL DEATH; CELL PROLIFERATION; CYTOTOXICITY; DRUG TARGETING; EXON; GENE MUTATION; GENE TARGETING; HUMAN; MACROMOLECULE; ONCOGENE; POINT MUTATION; REVIEW; RNA SPLICING; SPLICEOSOME; STRUCTURE ACTIVITY RELATION;

ALTERNATIVE SPLICING; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHOSPHOPROTEINS; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; SPLICEOSOMES;

EID: 84871924824     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.07.013     Document Type: Review

References (61)

1. D.E. Egecioglu, and G. Chanfreau Proofreading and spellchecking: a two-tier strategy for pre-mRNA splicing quality control RNA 17 2011 383 389
2. C.L. Will, and R. Luhrmann Spliceosome structure and function Cold Spring Harb. Perspect. Biol. 3 2011 10.1101/cshperspect.a003707
3. J. Karijolich, and Y.T. Yu Spliceosomal snRNA modifications and their function RNA Biol. 7 2010 192 204
4. M.C. Wahl The spliceosome: design principles of a dynamic RNP machine Cell 136 2009 701 718
5. F. Pagani, and F.E. Baralle Genomic variants in exons and introns: identifying the splicing spoilers Nat. Rev. Genet. 5 2004 389 396
6. R.F. Luco, and T. Misteli More than a splicing code: integrating the role of RNA, chromatin and non-coding RNA in alternative splicing regulation Curr. Opin. Genet. Dev. 21 2011 366 372
7. J.W. Han Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus Nat. Genet. 41 2009 1234 1237
8. M.E. Baser The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2 J. Med. Genet. 42 2005 540 546
9. G.S. Wang, and T.A. Cooper Splicing in disease: disruption of the splicing code and the decoding machinery Nat. Rev. Genet. 8 2007 749 761
10. A. Kar Tau alternative splicing and frontotemporal dementia Alzheimer Dis. Assoc. Disord. 19 suppl 1 2005 S29 S36
11. L.B. Gardner Nonsense-mediated RNA decay regulation by cellular stress: implications for tumorigenesis Mol. Cancer Res. 8 2010 295 308
12. Y. Mizui Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities J. Antibiot. (Tokyo) 57 2004 188 196
13. T. Sakai Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. I. Taxonomy, fermentation, isolation and screening J. Antibiot. 57 2004 173 179
14. R.M. Kanada Total synthesis of the potent antitumor macrolides pladienolide B and D Angew. Chem. Int. Ed. Engl. 46 2007 4350 4355
15. H. Nakajima New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action J. Antibiot. (Tokyo) 49 1996 1204 1211
16. H. Nakajima New antitumor substances, FR901463, FR901464 and FR901465. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities J. Antibiot. (Tokyo) 49 1996 1196 1203
17. H. Nakajima New antitumor substances, FR901463, FR901464 and FR901465. III. Structures of FR901463, FR901464 and FR901465 J. Antibiot. (Tokyo) 50 1997 96 99
18. M. Miller-Wideman Herboxidiene, a new herbicidal substance from Streptomyces chromofuscus A7847. Taxonomy, fermentation, isolation, physico-chemical and biological properties J. Antibiot. (Tokyo) 45 1992 914 921
19. Y. Sakai GEX1 compounds, novel antitumor antibiotics related to herboxidiene, produced by Streptomyces sp. I. Taxonomy, production, isolation, physicochemical properties and biological activities J. Antibiot. (Tokyo) 55 2002 855 862
20. Y. Kotake Splicing factor SF3b as a target of the antitumor natural product pladienolide Nat. Chem. Biol. 3 2007 570 575
21. D. Kaida Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA Nat. Chem. Biol. 3 2007 576 583
22. M. Hasegawa Identification of SAP155 as the target of GEX1A (Herboxidiene), an antitumor natural product ACS Chem. Biol. 6 2011 229 233
23. C.F. Thompson Total synthesis of FR901464. Convergent assembly of chiral components prepared by asymmetric catalysis J. Am. Chem. Soc. 122 2000 10482 10483
24. C.F. Thompson FR901464: total synthesis, proof of structure, and evaluation of synthetic analogues J. Am. Chem. Soc. 123 2001 9974 9983
25. M. Horigome A synthesis of FR901464 Tetrahedron Lett. 42 2001 8207 8210
26. H. Motoyoshi Structure-activity relationship for FR901464: a versatile method for the conversion and preparation of biologically active biotinylated probes Biosci. Biotechnol. Biochem. 68 2004 2178 2182
27. B.J. Albert Total synthesis of FR901464, an antitumor agent that regulates the transcription of oncogenes and tumor suppressor genes J. Am. Chem. Soc. 128 2006 2792 2793
28. H. Motoyoshi Total synthesis of FR901464: second generation Tetrahedron 62 2006 1378 1389
29. B.J. Albert Total syntheses, fragmentation studies, and antitumor/antiproliferative activities of FR901464 and its low picomolar analogue J. Am. Chem. Soc. 129 2007 2648 2659
30. B.J. Albert Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells Mol. Cancer Ther. 8 2009 2308 2318
31. S. Osman Structural requirements for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464 Chemistry 17 2011 895 904
32. C. Lagisetti Antitumor compounds based on a natural product consensus pharmacophore J. Med. Chem. 51 2008 6220 6224
33. C. Lagisetti Synthetic mRNA splicing modulator compounds with in vivo antitumor activity J. Med. Chem. 52 2009 6979 6990
34. L. Fan Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing ACS Chem. Biol. 6 2011 582 589
35. A. Corrionero Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A Genes Dev. 25 2011 445 459
36. S. Germann Splicing programs and cancer J. Nucl. Acids 2012 269570
37. E.G. Folco The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region Genes Dev. 25 2011 440 444
38. A. Corvelo Genome-wide association between branch point properties and alternative splicing PLoS Comput. Biol. 6 2010 E1001016
39. R. Furumai Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF Cancer Sci. 101 2010 2483 2489
40. F. Menghi Genome-wide analysis of alternative splicing in medulloblastoma identifies splicing patterns characteristic of normal cerebellar development Cancer Res. 71 2011 2045 2055
41. C. Ghigna Alternative splicing and tumor progression Curr. Genomics 9 2008 556 570
42. N. Allende-Vega p53 is activated in response to disruption of the pre-mRNA splicing machinery Oncogene 2012 10.1038/onc.2012.38 (Epub ahead of print)
43. M.K. Gundluru Design, synthesis and initial biological evaluation of a novel pladienolide analog scaffold MedChemComm 2 2011 904 908
44. L. Qin ER stress negatively regulates AKT/TSC/mTOR pathway to enhance autophagy Autophagy 6 2010 239 247
45. B.M. Emerling, and A. Akcakanat Targeting PI3K/mTOR signaling in cancer Cancer Res. 71 2011 7351 7359
46. A. Efeyan, and D.M. Sabatini mTOR and cancer: many loops in one pathway Curr. Opin. Cell Biol. 22 2010 169 176
47. F. Damm SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications Leukemia 26 2011 1137 1140
48. C.N. Hahn, and H.S. Scott Spliceosome mutations in hematopoietic malignancies Nat. Genet. 44 2011 9 10
49. T.L. Lasho SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients Leukemia 26 2011 1135 1137
50. L. Malcovati Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms Blood 118 2011 6239 6246
51. E. Papaemmanuil Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts N. Engl. J. Med. 365 2011 1384 1395
52. V. Quesada Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia Nat. Genet. 44 2011 47 52
53. D. Rossi Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness Blood 118 2011 6904 6908
54. L. Wang SF3B1 and other novel cancer genes in chronic lymphocytic leukemia N. Engl. J. Med. 365 2011 2497 2506
55. K. Yoshida Frequent pathway mutations of splicing machinery in myelodysplasia Nature 478 2011 64 69
56. S. Hirabayashi Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML Blood 119 2012 E96 E99
57. M.M. Patnaik SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value Blood 119 2012 569 572
58. T.A. Graubert Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes Nat. Genet. 44 2012 53 57
59. A. Yokoi Biological validation that SF3b is a target of the antitumor macrolide pladienolide FEBS J. 278 2011 4870 4880
60. A. Kramer The structure and function of proteins involved in mammalian pre-mRNA splicing Annu. Rev. Biochem. 65 1996 367 409
61. V. Visconte SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts Leukemia 26 2012 542 545